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The primary objective of this work was to identify a biomarker candidate expressed during hemangioma growth, but not during involution. Specifically, our objective was to observe expression of this biomarker candidate in untreated hemangioma patients over time to establish baseline patterns of expression. The ideal biomarker would be obtained noninvasively in urine. Based on our previous work, we had two potential candidates for a urine biomarker, including monocyte chemoattractant protein-1 and 8-hydroxy-2′-deoxyguanosine. 8, 9 However, the concentration of these molecules in the urine could be affected by conditions other than hemangioma proliferation. We sought to identify a microRNA biomarker candidate. MicroRNAs are small noncoding RNA molecules generally 21 to 25 nucleotides in length that regulate biological responses by targeting multiple genes in a specific biological pathway. Thus, microRNAs constitute an upstream "hub" capable of targeting multiple downstream sites for amplified and potentially synergistic effects. In this case, we were looking for a microRNA that regulated angiogenesis, and microRNA-126 is identified in the literature as a master "angiomiR." [10] [11] [12] [13] Furthermore, microRNAs are excreted from cells in exosomes and have been identified in serum and urine as potential biomarkers for multiple pathologic conditions, [14] [15] [16] making recovery from urine a viable option.
Doppler ultrasound is the screening test of choice for diagnosing hemangiomas on the basis of flow velocity patterns. Arteriovenous malformations and hemangiomas have high flow velocities, with hemangiomas distinguished from arteriovenous malformations by the presence of tumor stroma. 17 The secondary objectives of this work were to examine quantitative changes in hemangioma size and flow velocities as surrogate markers for hemangioma growth and involution and to establish the baseline patterns of changes of these values in children with untreated hemangiomas. These objectives were addressed through the longitudinal collection of ultrasound measurements in children with hemangiomas. The biomarker data were compared with ultrasound measurements to determine how changes in biomarker abundance correlate with changes in ultrasound measurements.
MATERIALS AND METhODS

RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction
Detection of miRNA was performed as described previously. 18, 19 Briefly, total RNA from cells was extracted using the miRVana miRNA isolation kit according to the manufacturer's protocol (Thermo Fisher Scientific, Waltham, Mass.). Levels of microRNA expression in each sample were determined by microRNA TaqMan assays and the TaqMan microRNA reverse transcription kit, followed by quantitative real-time polymerase chain reaction using the Universal PCR Master Mix (Thermo Fisher Scientific). The probe sequences used for microRNA quantitative real-time polymerase chain reaction are listed in Table 1 .
Results of quantitative real-time polymerase chain reaction were reported as fold change in the target gene relative to the endogenous control microRNA and calculated using the 2 -Δ(ΔCt) method as described previously. 18, [20] [21] [22] human Subjects Protocol A prospective longitudinal study was conducted in children with hemangioma (n = 34) and age-matched healthy volunteers (n = 34). Subjects were enrolled through the Hemangioma and Vascular Malformation Clinic and the Primary Care Clinic at Nationwide Children's Hospital. Inclusion criteria were the presence of a hemangioma on the skin greater than or equal to 1 cm in diameter with diagnosis confirmed by Doppler ultrasound, and age 5 months or younger to ensure that data were captured while hemangiomas were still in the proliferation stage. Exclusion criteria were treatment of hemangioma before or during the study, taking steroids or propranolol for other comorbidities, hemoglobinopathies, PHACES (i.e., posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities, sternal cleft, and supraumbilical raphe) syndrome, rapidly involuting or noninvoluting congenital hemangiomas, and parents/guardian unable to provide informed consent. Doppler ultrasound was used to confirm the diagnosis of hemangioma. Data collection was performed at 2, 4, 6, 9, 12, 18, and 24 months of age ± 2 weeks. Bag urine samples and Doppler ultrasound were obtained on the same visit for hemangioma subjects and urine alone was obtained for healthy controls. Subjects that missed study visits were allowed to continue in the study.
Urine RNA Isolation
Detection of microRNA in the urine was performed using the miRCURY RNA Isolation Kit-Biofluids (Exiqon, Vedbaek, Denmark) kit according to the manufacturer's protocol. A minimum sample volume of 3 ml of urine was needed for testing, and samples were centrifuged to remove pelleted debris. The quality and quantity of total RNA was measured using the NanoDrop 2000 Spectrophotometer (NanoDrop Products, Wilmington, Del.) as described earlier. 23 RNA quality was detected by ultraviolet absorbance at 260/280 nm. Samples with optical density 260/280 nm ratios greater than or equal to 1.6 and less than or equal to 2.0 were used for quantitative real-time polymerase chain reaction measurements. One hundred nanograms of total RNA was used to make cDNA for each microRNA.
Ultrasound Evaluation
Gray-scale evaluation was used to assess the size and borders of the hemangioma. Color Doppler images were obtained to evaluate degree of internal vascularity using the same sensitivity setting to monitor changes over time. Spectral Doppler recordings were performed to assess the relative amount of diastolic flow within the lesion, to reflect the degree of arteriovenous shunting. When possible, angle-corrected velocities were recorded to allow monitoring of proliferation or involution of the hemangioma. Systolic waveform velocity measurements and resistive indices were calculated in triplicate (if possible) to evaluate changes in the vascular flow over time during the hemangioma growth and involution phases. Because it was not always possible to determine the precise orientation of feeding or internal vessels because of vessel tortuosity, the Doppler frequency shift was also recorded. Studies were performed using a Philips iU22 ultrasound system (Philips, Eindhoven, The Netherlands) with high-frequency linear array transducers operating between 8 and 17 MHz. Calculation of tumor volume was performed as described by Feldman et al. 24 
Statistical Analysis
The objective of this longitudinal observational study was to collect preliminary data of the changes of selected biomarkers from ultrasound measures (volume and blood flow velocity) and urine samples (MCP-1 and microRNA) in children with hemangioma, and compare the difference with age-matched control subjects at different time points. A sample size of 26 patients and 26 normal age-matched control subjects was proposed to detect an effect size of 0.8 SD difference based on a two-sided two-sample t test with 80 percent power at α = 0.05. All data analysis was conducted using SAS 9.4 (SAS Institute, Inc., Cary, N.C.). Linear mixed models for repeated measures with autoregressive variance-covariance structure were used to estimate the changes of tumor volume, microRNA-126, and blood flow velocity over time. For each measure, the means and the standard errors at each time point were estimated using the LSMEANS statement in the GLIMMIX procedure. The covariance structure was chosen based on Akaike information criterion/Bayesian information criterion. Sensitivity analyses were conducted using different models and covariance structure to ensure that the results were consistent with the selection of the models. The correlations between the microRNA-126 levels and the tumor volumes at each time point (4, 6, and 9 months) were summarized using the Spearman correlation because of the nonnormal distribution of the variables. The microRNA-126 differences between the hemangioma patients and the healthy controls were compared using the two-sample t test. Sensitivity analysis was also conducted using the two-sample rank test. A value of p < 0.05 was considered statistically significant.
RESULTS
Identification of a housekeeping microRNA for quantitative real-time polymerase chain reaction standardization was performed by measuring commonly reported urinary microRNA in samples from healthy age-matched controls (n = 6) and children with hemangiomas (n = 6). Results were summarized as mean ± SD and differences between control and hemangioma groups were analyzed using the t test. Normality test of the residual from the mixed models and the sensitivity analysis using two-sample rank test method were Plastic and Reconstructive Surgery • June 2017 also conducted to ensure the robustness of our conclusions from the t test. Data were normalized to values observed for the healthy age-matched controls and reported as fold-change differences for children with hemangiomas. MicroRNA-30a is known to be highly abundant in urine from children and had equivalent abundance in both subject groups (Table 2) ; thus, this was selected as the housekeeping microRNA. 25 All urine samples that had enough volume to yield sufficient amounts of adequate quality microRNA were analyzed by quantitative real-time polymerase chain reaction. MicroRNA-126 abundance was significantly elevated in the hemangioma group at ages 4 months and 6 months, but was not significantly different from healthy controls at age 9 months (Fig. 1) . The slight increase in microRNA-126 abundance at 9 months is attributed to two hemangioma children with elevated microRNA-126 levels at that time point, as the other seven subjects had levels of microRNA-126 abundance similar to healthy controls. A temporal pattern for microRNA-126 levels was identified, with elevation occurring at 4 and 6 months of age in the hemangioma group that normalized in most affected children by age 9 months.
Ultrasound measurements of hemangioma size and blood flow velocity were obtained to understand how these values change as hemangiomas progress from the proliferative to the involuting phase and to serve as an objective comparator for the microRNA-126 biomarker data. The numbers of subjects with both valid microRNA-126 and valid ultrasound measures were 14, 13, and 9 at the time points of 4, 6, and 9 months, respectively. The mean and standard errors of the blood flow velocities and volumes were estimated using the LSMEANS statement based on the linear mixed model for repeated measures. Mean blood flow velocities peaked at 4 months of age and declined progressively to age 24 months, with flow velocities that were roughly half the peak flow velocities observed at age 4 months (Fig. 2, above, left) . Blood flow velocity may peak at 4 months because this is when the rate of tumor growth is greatest based on the change in tumor volume from 2 to 4 months. Hemangioma size did not increase past 6 months of age and began to decrease in size between 9 and 12 months of age (Fig. 2 , above, 
Fig. 1.
MicroRNA-126 (miR126) is more abundant in urine of children with hemangiomas (HE) during the proliferative phase only. Urine specimens collected from children with hemangiomas and healthy age-matched controls at 4, 6, and 9 months of age show significantly increased abundance of microRNA-126 during hemangioma proliferation (4 and 6 months) that subsequently reverts to the baseline level when proliferation stops (9 months). Results are expressed as mean ± SD; *p < 0.05, t test; n = number of subjects analyzed.
right).
Representative ultrasound images for measuring flow velocity in a single subject are shown in Figure 2 , below. Temporal changes in volume are consistent with clinical observations where hemangiomas reach a plateau in size and gradually involute. In this cohort, there was no additional growth after 6 months of age, and the plateau in hemangioma growth occurred between 6 and 9 months of age. Scatter plots were used to visually evaluate whether urinary microRNA-126 abundance correlated with hemangioma size at ages 4, 6, and 9 months. All subjects that had microRNA-126 quantitative real-time polymerase chain reaction values and ultrasound volume measurements were included in the analysis. At 4 months of age, there was a moderately strong correlation between hemangioma size and urinary microRNA abundance (Fig. 3, above) . Increased urinary microRNA-126 abundance was detectable for all hemangiomas. At 6 months, there was a moderately strong correlation between hemangioma size and microRNA-126 abundance. All hemangiomas had increased microRNA-126 abundance compared with controls. This was most pronounced at age 6 months (Fig. 3, center) . In the 6-month group, there was one subject that was treated as an outlier and not included in the calculation of the Spearman correlation coefficient. In this subject, the relative abundance of microRNA-126 was higher at 4 months (11.18-fold change) compared to 6 months (9.93-fold change), with a corresponding decrease in tumor volume from 18.6 cm 3 to 13.2 cm 3 , indicating that this hemangioma was beginning to involute before age 6 months. The clinical course for this subject indicates that this was likely a rapidly involuting congenital hemangioma, which should have been excluded. By 9 months of age, microRNA-126 abundance for all hemangioma subjects decreased, so that there Plastic and Reconstructive Surgery • June 2017 was no statistically significant difference in values between hemangioma subjects and age-matched controls. For two subjects, relative microRNA-126 abundance was high, but it was decreasing. The decrease from 6 months to 9 months was 62.58-to 31.21-fold for one subject and 15.17-to 13.6-fold for the other subject. All other subjects had microRNA-126 abundance levels that essentially dropped to levels observed with healthy controls even though the hemangiomas were still present (Fig. 3, right) . This indicates that the expression of microRNA-126 is not needed to maintain hemangioma tumor volume and that the biology of the hemangioma has changed.
DISCUSSION
In 1998, the National Institutes of Health Biomarkers Definition Working Group defined a biomarker as "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention." 26 There have been previous attempts to identify urine biomarkers for hemangioma. In a study reported by Marler et al., elevation of urinary matrix metalloproteinase (MMP)-2, MMP-9, basic fibroblast growth factor, or vascular endothelial growth factor was not observed in children with infantile hemangioma. However, they did identify two high-molecular-weight matrix metalloproteases in 60 percent of children with hemangiomas. 27 Kleber et al. monitored urinary MMP-2 and MMP-9 levels in response to propranolol treatment of hemangiomas and found increased MMP-2 levels but no changes in MMP-9 levels. 28 However, MMP-2 and MMP-9 are found in the urine of healthy children in response to normal tissue remodeling; thus, the levels of these proteins are not necessarily specific for hemangioma growth. 29 At this time, there is no urine biomarker that has been adopted on a widespread clinical basis to monitor growth of infantile hemangioma.
There is evidence that points to microRNA-126 as a potential biomarker for hemangiomas, as it is the most abundant microRNA in fetal endothelial cells. 30, 31 Endothelial cell-specific expression of microRNA-126 regulates endothelial cell proliferation, development of fetal vasculature, and vascular integrity. 31, 32 Expression of microRNA-126 is substantially elevated during fetal development and drops significantly postpartum, 31, [33] [34] [35] which is consistent with the theory of hemangiomas as fetal rests. 10, 12 These results provide the first evidence that elevated urinary microRNA-126 levels can be measured and used as an indicator for hemangioma growth in affected children. The elevated levels and correlation between hemangioma size Fig. 3 . Urinary microRNA-126 (miR-126) abundance correlates with tumor size. The Spearman correlation coefficient (R) indicates a moderately strong positive correlation between urinary microRNA-126 abundance and tumor volume that is observed during hemangioma proliferation at (above) 4 months and (center) 6 months of age, but not at 9 months of age (below). The circled value (center) was excluded as a rapidly involuting congenital hemangioma. n, number of subjects analyzed.
and microRNA-126 abundance at 4 and 6 months, the drop in microRNA-126 expression once proliferation stops, along with essentially undetectable levels of microRNA-126 in control subjects indicate that hemangiomas are the source of the microRNA-126. Thus, microRNA-126 meets the biomarker criterion as, "a characteristic that is objectively measured and evaluated as an indicator of … pathogenic processes."
These are the first reported longitudinal ultrasound data for changes in blood flow velocity and tumor volume in children with untreated hemangiomas. As with the microRNA biomarker, it is important to establish the changes in ultrasound measurements over time to determine whether this method of monitoring hemangiomas has merit for future studies. In addition, the ultrasound data were collected to provide quantitative data that document changes in hemangioma size and to correlate these findings with microRNA-126 abundance levels. Ultrasound data are challenging to use because hemangioma size and blood flow will change if the child is crying, and we could not control for this variable. Nonetheless, the changes in blood flow velocity and tumor volume observed in this study are consistent with a report by Chang et al. that performed serial measurements (using tape measures) of hemangioma growth on 367 children. They found that 80 percent of hemangioma growth was complete by age 5 months, and 97 percent had completed proliferation by age 9 months. 36 Both ultrasound and microRNA-126 data reported in this study are consistent with this clinical picture. Thus, ultrasound monitoring of flow velocity and size may be a reasonable surrogate for monitoring changes in hemangioma growth and proliferation, but collection of additional data is need to validate this method of monitoring.
Performing a longitudinal study on infants and small children with minimal compensation or incentive for participation (i.e., no treatment) was a significant challenge. Many subjects either dropped out, missed study visits, or the urine samples were not adequate for testing. As a result, the number of valid samples at each time point was much smaller than expected. The team is greatly indebted to the parents who did bring their children for 2-hour study visits, as their only real incentive was to help future children born with hemangiomas. Nonetheless, the results provide critical first evidence that justifies performing additional studies to validate microRNA-126 as a biomarker. These are the first reported results of a microRNA biomarker for hemangiomas and the only reported urine biomarker for hemangiomas with elevated expression only during the proliferative phase. This work provides a new paradigm for identifying the transition from hemangioma growth to involution. These results provide an important baseline for future studies to test whether urinary microRNA-126 levels decrease in response to therapeutic intervention. The use of quantitative values derived from biological events that can be used as surrogate endpoints to monitor hemangioma proliferation and involution will enable investigators to test new treatments for hemangiomas, so that all children with hemangiomas can be safely treated. 
